Related Experiment Video
Updated: May 21, 2026
07:52
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Lipid disorders in uremia and dialysis
1ASH Comprehensive Hypertension Centre, University of Chicago Medicine, Chicago, Ill., USA.
Contributions to Nephrology
|June 2, 2012
Summary
Cholesterol treatment lowers cardiovascular risk in chronic kidney disease (CKD) patients not on dialysis. However, it does not significantly slow kidney disease progression or reduce mortality in those on dialysis.
Area of Science:
- Nephrology
- Cardiology
- Clinical Pharmacology
Background:
- Cholesterol management is crucial for cardiovascular risk reduction in chronic kidney disease (CKD).
- The efficacy of cholesterol reduction on cardiovascular outcomes and nephropathy progression in advanced CKD, particularly in dialysis patients, remains a key clinical question.
- Dyslipidemia in CKD exhibits unique characteristics, including altered high-density lipoprotein (HDL) function and increased low-density lipoprotein (LDL) oxidation, potentially impacting treatment effectiveness.
Purpose of the Study:
- To review the role of cholesterol management in reducing cardiovascular risk for patients with advanced CKD.
- To analyze randomized trial data regarding the impact of cholesterol-lowering therapies on cardiovascular events and kidney disease progression.
- To provide guidance on statin dosing and explore adjunctive therapies for lipid management in CKD stages 3b-5.
Main Methods:
- Review of biochemical aspects of lipids in uremia.
- Analysis of randomized controlled trial data on cholesterol-lowering treatments in CKD patients.
- Discussion of statin pharmacology and safety in different stages of CKD.
Main Results:
- Cholesterol reduction significantly decreases cardiovascular risk in CKD patients with estimated glomerular filtration rate (eGFR) >15 ml/min not on dialysis.
- Cholesterol reduction does not significantly slow nephropathy progression or reduce mortality in patients undergoing dialysis.
- Specific statins require dose adjustments in stage 3b or higher CKD due to safety concerns, with atorvastatin and pravastatin being exceptions.
Conclusions:
- Cholesterol management is beneficial for cardiovascular risk reduction in non-dialysis CKD patients.
- The benefits of cholesterol reduction are less clear for slowing kidney disease progression and reducing mortality in dialysis patients.
- Careful consideration of statin dosing and potential adjunctive therapies is necessary for lipid management in advanced CKD.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:24Hemodialysis II: Procedure and Complications
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:18Chronic Kidney Disease IV: Nursing Management
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...